SERINA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.41 USD | -0.95% |
|
-4.37% | -.--% |
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales 1 | 3.465 | 0.5915 | 3.154 |
| EBITDA 1 | -1.598 | -2.209 | -3.039 |
| EBIT 1 | -1.632 | -2.27 | -3.128 |
| Operating Margin | -47.09% | -383.83% | -99.18% |
| Earnings before Tax (EBT) 1 | -1.265 | -2.682 | 5.27 |
| Net income 1 | -1.265 | -2.682 | 5.27 |
| Net margin | -36.5% | -453.44% | 167.11% |
| EPS 2 | -0.5900 | -1.250 | 1.455 |
| Free Cash Flow | - | -1.218 | -1.825 |
| FCF margin | - | -205.91% | -57.87% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 11/14/23 | 11/14/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | - | 1.28 | - |
| Net Cash position 1 | 0.91 | - | 3.92 |
| Leverage (Debt/EBITDA) | - | -0.5778 x | - |
| Free Cash Flow | - | -1.22 | -1.82 |
| ROE (net income / shareholders' equity) | - | 268% | 594% |
| ROA (Net income/ Total Assets) | - | -105% | -39.8% |
| Assets 1 | - | 2.554 | -13.24 |
| Book Value Per Share 2 | -16.40 | -17.00 | -13.10 |
| Cash Flow per Share 2 | 0.1500 | 0.2400 | 3.090 |
| Capex 1 | 0.08 | 0.01 | 0.5 |
| Capex / Sales | 2.45% | 1.64% | 15.98% |
| Announcement Date | 11/14/23 | 11/14/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 79.17M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- AGE Stock
- Financials Serina Therapeutics, Inc.
